R. Lee Buckler: How RepliCel Is Harnessing the Awesome Power of Cell Therapy

SAN FRANCISCO, CA--(Marketwired - Nov 10, 2014) -  Regenerative medicine and cell therapies hold possibilities for achieving near miracles in a multitude of indications, from life-saving treatments to aesthetic applications. RepliCel Life Sciences Inc. (TSX VENTURE: RP) (OTCQB: REPCF) is tackling a mix of medical and cosmetic issues that include hair regeneration, repair of painful and debilitating tendon injuries and rejuvenation of damaged skin. In this interview with The Life Sciences Report, R. Lee Buckler, the company's new vice president of business and corporate development, discusses his firm's innovative technology platform and the upcoming milestones that could affect its shares.

The Life Sciences Report: What kind of work has RepliCel been doing in the cell therapy field?

R. Lee Buckler: When CEO and President David Hall took over the company in 2011, it was built around hair regeneration. That is still an important part of our portfolio; however, he had a vision for broadening the technology and building a platform, which the company has now executed.

We are preparing to launch a very significant Phase 2 trial using our RCH-01 (dermal sheath cup [DSC] cells) for hair regeneration. This is a cellular injection -- a cell transplant rather than a hair transplant -- and is an important evolution because...

Continue reading this interview with R. Lee Buckler: How RepliCel Is Harnessing the Awesome Power of Cell Therapy

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends.

DISCLOSURE:

RepliCel Life Sciences Inc. paid The Life Sciences Report to conduct, produce and distribute the interview. R. Lee Buckler had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of R. Lee Buckler and not of The Life Sciences Report or its officers.